Clinical Trials
53 trialsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
M.D. Anderson Cancer Center
GRAPE
Nagoya University
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
EV-201
Astellas Pharma Inc
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
ATLAS
pharmaand GmbH
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Fox Chase Cancer Center
Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
UNICANCER
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
VINGEM
Karolinska University Hospital
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
SWOG Cancer Research Network
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Memorial Sloan Kettering Cancer Center
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Memorial Sloan Kettering Cancer Center
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Urothelial Cancer
National Cancer Institute (NCI)
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
SWOG Cancer Research Network
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
SWOG Cancer Research Network
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
SWOG Cancer Research Network
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
SWOG Cancer Research Network
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
M.D. Anderson Cancer Center
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC